Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.48

+3.4%

10:48 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (13370)	10/6/2004 10:21:38 PM
From: Biomaven	Read Replies (1) of 52153

scenarios are relevant to valuation to a degree Absolutely on point for this thread. Interesting what you are suggesting - usually people here are on the other side of these straddles or strangles (as rkrw recently successfully was with AGIX). What's different here is that the imnplied volatilities are very high for a distant maturity - that's very unusual. If Stellar 3 is a big success, the stock could go above $16 given that right now there appears to be considerable skepticism on the street about the trial (and about the company) and there is a big short position. So that perhaps argues for the buy/write as the better strategy. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next